iJOBS Virtual Site Visit: Bristol Myers Squibb
Tuesday, July 21, 2020
10:30 am

Rao V. Mantri, PhD
Vice President & the Head of Drug Product Development
rao.mantri@bms.com

Rao V. Mantri is Vice President & the Head of Drug Product Development at Bristol-Myers Squibb. Rao is responsible for development of BMS drug product portfolio and delivering solutions to address drug delivery challenges for different molecular modalities. Since joining BMS in 2000, he has held positions of increasing responsibility in design, development and technology transfer of small molecules and biologics drug products. He has broad experience in discovery support, formulation development, process engineering, materials science, analytical sciences and leading multi-disciplinary CMC teams. He has contributed to development of many clinical drug products and several commercial drug products including Onglyza®, Kombiglyze®, Baraclude®, Empliciti® and Opdivo®. He has published several manuscripts, book chapters & patents and is a co-editor of "Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice". Rao served on Industrial Expert Leadership committees at USP, IQ and NSF C-SOP. Rao received his B. Tech (Chemical Engineering) in India, M.S. (Chemical Engineering) & PhD (Pharmaceutical Chemistry) from the University of Kansas and Executive MBA from MIT-Sloan.

Madhavi Srikoti, Ph.D.
Senior Research Investigator
madhavi.srikoti@bms.com

Senior Research Investigator in the Analytical Sciences division of the Drug Product Development department. She obtained her doctorate degree in the field of Analytical Chemistry. She has been working with Bristol Myers Squib (BMS) for the past 14 years. Since coming to BMS, she has worked on developing and validating analytical methods for a number of projects. In her current role, she is responsible for managing analytical activities to support early phase and formulation development for late stage pediatric and adult projects. In addition, as an analytical project leader, Dr. Srikoti is responsible for ongoing analytical activities at contract labs, executing technology transfers, supporting IND, NDA and Rest of the World filings and addressing health authority questions. She is also an operation lead to oversee everyday activities performed at BMS business partners. Currently, she is working on improving her knowledge in understanding user needs, patient and drug journey in addition to enhancing her expertise in pediatric fixed dose combination products.

Michael S. Little, PhD
Research Investigator
Michael.Little@bms.com

Michael earned a B.S. degree in Chemistry from Montclair State University in 2013 and his Ph.D. in Chemistry from the University of North Carolina in 2018. His doctoral work focused on the elucidation of protein structure-function correlation using protein crystallography and biochemical/biophysical assays. Michael has received numerous honors and awards in both undergraduate and graduate schools, including a fellowship from the National Science Foundation (NSF). In June 2018, he joined the Drug Product Development Department of Bristol Myers Squibb as a Research Investigator I. Michael's work focuses on physical and chemical degradation of proteins that can occur during development and manufacturing. His current research interests include late stage pharmaceutical development of novel biologics.

Dolapo Olusanmi, PhD
Principal Scientist
Dolapo.Olusanmi@bms.com

Dolapo Olusanmi is a Principal Scientist with 10+ years' experience at Bristol Myers Squibb (BMS). Following her Ph.D. in Chemical Engineering on milling and fracture mechanics, she joined the drug product development group at BMS, UK, before taking on a new opportunity at BMS in New Jersey 8 years ago. Dolapo's expertise is at the interface of small molecule drug substance and drug product development. She has led development teams from early stage development to commercial validation of drug products, achieving successful product robustness, launch and filing. Dolapo is an established multi-project matrix team leader employing risk-balanced decision making to advance portfolio programs both in the early and late stages. Her current role is in strategic drug product innovation to identify opportunities for further delivery of value to patients and enhancement of their experience of BMS drugs.

Erinc Sahin, PhD
Vice President & the Head of Drug Product Development
Erinc.Sahin@bms.com

Dr. Sahin received his B.S in Molecular Biology and Genetics in METU (Turkey), M.Sc. in a joint program between Bioengineering and Materials Science & Engineering departments in Sabanci University (Turkey); and his Ph.D. in a joint program between Biochemistry and Materials Science & Engineering departments in University of Delaware (USA). Prior to joining BMS in 2011, Dr. Sahin worked on aggregation of therapeutically relevant proteins as a post-doctoral fellow in Roberts group in Department of Chemical and Biomolecular Engineering in University of Delaware. Since joining BMS in 2011, Dr Sahin has taken roles with increasing complexities and responsibilities in a group that develops formulations, manufacturing processes, and patient-centric product presentations for injectable drug products, from their discovery to commercialization.